Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed · Phase 2

Conditions studied: Burkitt's Lymphoma, Burkitt'S-like Lymphoma

In brief

The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.

Key facts

Study ID

NCT00669877

Run by

M.D. Anderson Cancer Center

People needed

56

Starts

2002-08-01

Expected to finish

2015-10-01

Last updated by the study team

2018-05-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Burkitt's or Burkitt-like leukemia and/or lymphoma, either previously untreated, previously treated (may be in CR or with active disease after 1-2 courses of chemotherapy), or HIV-related.
• All ages are eligible.
• Zubrod performance status < 3 (ECOG Scale, Appendix A).
• Adequate liver function (bilirubin < 3.0 mg/dL, unless considered due to tumor), and renal function (creatinine < 3.0 mg/dL, unless considered due to tumor).
• Signed informed consent.

You may not qualify if…

• N/A

Where it is running

• The University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.